Bank of New York Mellon’s China Pharma Holdings CPHI Stock Holding History

Bank of New York Mellon’s Portfolio CPHI Stock Details CPHI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-26	Closed	-$4K	–	4220
2018 Q1	$4K	Buy	+26	New	+$4.65K	﹤0.01%	4306
2017 Q2	–	Sell	-48	Closed	-$6K	–	4304
2017 Q1	$6K	Buy	+48	New	+$6.09K	﹤0.01%	4266

Other funds holding CPHI

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Glenhill Advisors New York $6.94M AUM 24.62% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of New York Mellon's CPHI Position: Q2 2018 in Review

Bank of New York Mellon sold out of China Pharma Holdings (CPHI) in Q2 2018, closing a stake of 26 shares — an estimated $4K sold.

Bank of New York Mellon first reported a position in CPHI in Q1 2017 and held it in 2 quarters. The position peaked at $6K in Q1 2017. 9 funds tracked by Wall St. Rank hold CPHI as of Q2 2018.

Bank of New York Mellon reported no remaining China Pharma Holdings position as of Q2 2018 after selling out during the quarter.
Bank of New York Mellon sold 26 China Pharma Holdings shares in Q2 2018, an estimated $4K.
Bank of New York Mellon first reported a position in China Pharma Holdings in Q1 2017 and held it in 2 quarters.
Bank of New York Mellon's China Pharma Holdings position peaked at $6K in Q1 2017.
9 funds tracked by Wall St. Rank held China Pharma Holdings as of Q2 2018.

Based on Bank of New York Mellon's 13F filing for Q2 2018, filed 6 Aug 2018.